Results 91 to 100 of about 14,564 (189)

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Xue W, Haig J, Régnier SA, Malcolm W   +3 more
core  

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Therapeutic Advances in Ophthalmology
What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in The Lancet scientific journal. • Wet age-related macular degeneration (or AMD) is a long-term eye disease in which abnormal blood vessels grow
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong   +20 more
doaj   +1 more source

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study

American Journal of Ophthalmology Case Reports
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty, Ashish Sharma, Soumen Mondal, Jay Sheth, Tushar Kanti Sinha, Subhendu Boral, Angshuman Mukherjee, Ranabir Bhattacharya, Ritobroto Maitra   +8 more
doaj   +1 more source

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study

, 2019
Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine the effect of intravitreal aflibercept injection on the corneal endothelium in patients with diabetic or
Muto T, Machida S
core  

EFFICIENCY OF AFLIBERCEPT IN CLINICAL PRACTICE

, 2017
Introduction. Age-related macular degeneration is a leading cause of severe vision loss worldwide, frequently resulting in legal blindness. Implementation of anti-VEGF therapy in clinical practice was an important milestone in the treatment of age ...
A. V. Kulagina
core   +1 more source

: Intravitreal aflibercept for macular edema due to CRVO

, 2014
International audiencePURPOSE: To evaluate the efficacy and safety of intravitreal aflibercept injections for treatment of macular edema secondary to central retinal vein occlusion (CRVO).
Vitti, Robert, Lorenz, Katrin, Ogura, Yuichiro, Hiemeyer, Florian, Stemper, Brigitte, Schmidt-Erfurth, Ursula, Zeitz, Oliver, Sandbrink, Rupert, Berliner, Alyson, J., Honda, Miki, Holz, Frank, G., Korobelnik, Jean-Francois, Roider, Johann, Simader, Christian   +13 more
core   +1 more source

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis

, 2017
Kimberly Spooner,1–3 Thomas Hong,1,2 Wijeyanthy Wijeyakumar,1–3 Andrew A Chang1–3 1Sydney Retina Clinic & Day Surgery, 2Sydney Institute of Vision Science, Sydney, 3Save Sight Institute, Department of Ophthalmology, University of ...
Chang AA, Spooner K, Hong T, Wijeyakumar W   +3 more
core  

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum]

, 2017
Korol AR, Zborovska O, Kustryn T, et al. Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study. Clin Ophthalmol.
Kustryn T, Korol AR, Zborovska O, Dorokhova O, Pasyechnikova N   +4 more
core  

Preclinical Investigations of Intravitreal Ziv-Aflibercept

, 2014
BACKGROUND and OBJECTIVE: To investigate the retinal safety of intravitreal (IVT) ziv-aflibercept in rabbits.MATERIALS and METHODS: Eighteen rabbits were given an IVT injection of ziv-aflibercept (25 mg/mL) or aflibercept (40 mg/mL) and examined by ...
Gabrielly Maria Denadai Chiarantin, Colicchio, Daniel [UNIFESP], Daniel Colicchio, Eduardo Büchele Rodrigues, Oliveira Dias, Joao Rafael de [UNIFESP], Novais, Eduardo Amorim [UNIFESP], Mariana Maurício Matioli, Verna, Carina [UNIFESP], Meyer, Carsten H. [UNIFESP], Tenorio Barros, Nilana Meza [UNIFESP], Farah, Michel Eid [UNIFESP], Eduardo Amorim Novais, João Rafael de Oliveira Dias, Carina Verna, Matioli, Mariana Mauricio [UNIFESP], Badaro, Emmerson [UNIFESP], Denadai Chiarantin, Gabrielly Maria [UNIFESP], Rodrigues, Eduardo Buchele [UNIFESP], Nilana Meza Tenório Barros, Carsten H. Meyer, Fernando Marcondes Penha, Penha, Fernando Marcondes [UNIFESP], Michel Eid Farah, Emmerson Badaró   +23 more
core   +1 more source

Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration

Scientific Reports
To compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj   +1 more source